A process for the manufacture of Form 1 ranitidine hydrochloride (N-[2-[[[5-(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2-nitro-1,1-ethenediamine) hydrochloride, is described. A process to convert ranitidine hydrochloride Form 2 to Form 1 is also described.

A process for the manufacture of Form 1 ranitidine hydrochloride (N-Ä2-ÄÄÄ5-(Dimethylamino)methylÜ-2-furanylÜmethylÜthioÜethyl-N'-methy l-2-nitro-1,1-ethenediamine) hydrochloride, is described. A process to convert ranitidine hydrochloride Form 2 to Form 1 is also described.

An effervescent pharmaceutical composition for oral use in the treatment of a condition mediated through histamine H2 receptors contains a therapeutically effective amount of ranitidine or a physiologically acceptable salt thereof, about 25-70% by weight of disodium citrate, and about 20-50% by weight of sodium bicarbonate. Optionally, the effervescent composition may also Include about 0.5-25% by weight of an edible organic acid such as fumaric acid. Preferably, the effervescent composition is ...

A process for the manufacture of pharmaceutical grade ranitidine base(N-[2-[[[5-(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2-nitro-1, 1-ethenediamine), is described. In-vitro and in-vivo pharmacological studies and acute toxicity studies indicate that it is as active and as safe as Form 2 ranitidine hydrochloride.

A process for the manufacture of Form 1 ranitidine hydrochloride (N-[2-[[[5-(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2-nitro-1,1-ethenediamine) hydrochloride, is described. A process to convert ranitidine hydrochloride Form 2 to Form 1 is also described.

A process for the manufacture of pharmaceutical grade ranitidine base(N-Ä2-ÄÄÄ5-(Dimethylamino)methylÜ-2-furanylÜmethylÜthioÜethyl-N'-m ethyl-2-nitro-1,1-ethenediamine), is described. In-vitro and in-vivo pharmacological studies and acute toxicity studies indicate that it is as active and as safe as Form 2 ranitidine hydrochloride.